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Abstract
Background
Psoriasis and inflammatory bowel disease (IBD) are chronic inflammatory diseases sharing
similar pathogenic pathways. Intestinal microbial changes such as a decrease of bakers’
yeast Saccharomyces cerevisiae have been reported in IBD, suggesting the presence of a
gut-skin axis.
Objective
To investigate whether the S. cerevisiae abundance was altered in psoriasis patients versus
healthy controls, and whether dimethylfumarate (DMF) interacted with this yeast.
Methods
Using qPCR, faecal samples were compared between psoriasis patients without DMF (n =
30), psoriasis patients with DMF (n = 28), and healthy controls (n = 32).
Results
Faecal S. cerevisiae abundance was decreased in psoriasis compared to healthy controls
(p<0.001). Interestingly, DMF use raised S. cerevisiae levels (p<0.001). Gastrointestinal
adverse-effects of DMF were correlated with a higher S. cerevisiae abundance (p = 0.010).
In vitro, a direct effect of DMF on S. cerevisiae growth was observed. In addition, anti-Sac-
charomyces cerevisiae antibodies were not elevated in psoriasis.
Conclusion
The abundance of baker’s yeast S. cerevisiae is decreased in psoriasis patients, but
appears to be restored upon DMF use. S. cerevisiae is generally classified as a yeast with
beneficial immunomodulatory properties, but may also be involved in the occurrence of
DMF’s gastrointestinal adverse-effects. Potentially, DMF might be a new therapy for IBD.
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Introduction
Psoriasis and inflammatory bowel disease (IBD) are chronic inflammatory diseases sharing
similar pathogenic pathways[1]. Both diseases are characterized by an increased inflammatory
response at the epithelial barrier. Secondly, similar genetic susceptibility plays an important
role in the development of both disease entities[2, 3]. A third contributing factor to IBD devel-
opment is an altered intestinal microbial composition, with a decreased abundance of several
commensal microbes (e.g. Faecalibacterium prausnitzii) and an increase of pathogens (e.g.
adherent invasive Escherichia coli)[4]. Changes in the fungal microbial community are also
common, with a decreased Saccharomyces cerevisiae abundance as one of the most prominent
observations[5]. S. cerevisiae, also called “baker’s yeast” or “brewer’s yeast” because of its usage
in fermentative production of bread, beer or wine, is the most intensively studied eukaryotic
organism in literature and one of the most abundant yeasts in our gut. S. cerevisiae is known to
possess anti-inflammatory properties by being able to stimulate IL-10 and inhibit TNF-α[5, 6].
Whether the fungal microbiome also plays a role in psoriasis is as yet unknown.
Dimethylfumarate (DMF) is an effective therapy for psoriasis, and an emerging therapy for
multiple sclerosis (MS)[7, 8]. There is growing interest for the implementation of DMF for
other chronic diseases such as IBD[9], although the exact mechanisms of action, besides
immunomodulation, have not yet been fully elucidated[10]. DMF has been also applied as a
biocide in shoe soles, clothes and furniture for prevention of mold growth. However, due to
allergic eczematous reactions, its use in these applications has been discontinued[11, 12].
As IBD and psoriasis share similar pathogenic pathways, including similar bacterial distur-
bances in the gut as we have recently shown[13], we speculated that, as in IBD, S. cerevisiae
abundance might be decreased in psoriasis. Interestingly, in Crohn’s disease, anti-Saccharomy-
ces cerevisiae antibodies (ASCAs) are significantly elevated compared to healthy controls[14,
15]. Recently, elevated ASCA levels have also been demonstrated in patients with spondyloar-
thritis[16], but in psoriasis this has not been studied.
In this study we investigated whether psoriasis patients harbor an altered faecal S. cerevisiae ab-
undance compared to healthy controls. Furthermore, in vivo and in vitro, we investigated whether
DMF had impact on the S. cerevisiae abundance. In addition, ASCA levels were measured.
Materials and methods
Patients
All patients were included at the outpatient clinic of the Department of Dermatology, Erasmus
MC in Rotterdam, the Netherlands. The study was approved by the medical ethical committee
of the Erasmus MC (MEC-2014-371). Written informed consent was obtained for all partici-
pants. Inclusion criteria were a confirmed psoriasis diagnosis by a dermatologist, and age
between 18–75 years. A minimum use of 6 weeks of DMF was required before inclusion in the
study. Exclusion criteria were oral antibiotic use 8 weeks prior to inclusion, IBD-comorbidity,
history of bowel resection, pregnancy and active infection. Clinical data was collected regard-
ing medical history, comorbidities, medication, and disease characteristics. Duration of DMF
use and presence of adverse-effects were recorded. Psoriasis Area and Severity Index (PASI)
was used to assess disease activity (<10 mild, 10–20 moderate,>20 severe). From every partic-
ipant, the faecal sample was sent by mail and stored at -80˚ Celsius within 48 hours.
A total of 49 psoriasis patients were included, of which the characteristics are depicted in
Table 1. In total 30 samples were collected from psoriasis patients without DMF. A total of 28
samples were collected from psoriasis patients with DMF. Of nine of these patients, two sam-
ples were collected, one sample before and one sample after (6–9 weeks) start of DMF.
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DNA isolation and quantitative polymerase chain reaction (qPCR)
DNA was extracted from 20 mg faeces per sample as described previously[13]. Briefly, 1 ml of
cell lysis buffer (Ambion, Life Technologies) was added, followed by 15 min incubation period.
Full cell lysis was achieved by bead-beating [three times 30s]. The samples were centrifuged,
whereupon 3:1 protein precipitation buffer (Promega) was added; 100% isopropanol [1:1] was
used to precipitate DNA from the supernatant; 100μl 70% ethanol was used to wash the DNA
pellet. Finally, DNA was resuspended in 50μl TE-buffer, DNA concentration was measured on
a Nanodrop spectrophotometer [Isogen Life Science BV, De Meern, The Netherlands] and
diluted to 10 ng/μl.
QPCR was performed two times as described[13]. QPCRs were performed in duplicate for
S. cerevisiae using the following primer:
F-AGGAGTGCGGTTCTTTG; R-TACTTACCGAGGCAAGCTACA[5].
Bacterial abundance analysis was performed by SybrGreen based qPCR reaction containing
20ng DNA [2μl of 10ng/μl], 9μL SYBR1Select MasterMix for CFX (ThermoFisher Scientific),
7μl dH20, 1μl 10μM forward primer, and 1μl 10μM reverse primer.
Thermocycle conditions comprised: denaturation step 10 min at 95˚C; 40 cycles of 95˚C
denaturation for 15s; 56˚C primer annealing for 30s; and 72˚C extension for 30s followed by a
standard melting
curve analysis. The mean was calculated from the two qPCRs and the S. cerevisiae abun-
dance was expressed in log10copies/gram faeces.
XTT assay
In vitro analysis was performed to establish whether the change in S. cerevisiae abundance was
directly or indirectly induced by DMF. The yeast S. cerevisiae (MycoBank#:163963) was
obtained from CBS-KNAW Fungal Biodiversity Centre, institute of the Royal Netherlands
Academy of Arts and Sciences. The yeast was cultured at 30˚C for 48 hours and 100μl of a
0.1McFarland yeast suspension was pipetted into a 96-well plate. Serial dilutions of DMF,
fumaric acid and an antimycotic (amphotericine-B-deoxycholate) were added to the cells in
triplicate. H20 and ethanol were used as vehicle control. XTT/PMS was added to the suspen-
sion as per manufacturers’ directions (Molecular Probes/Thermo Scientific) and the plate was
read after 24h at OD415 nm. Six independent experiments were performed.
ASCA measurement
Serum was collected of 30 psoriasis patients, including 18 without DMF and 12 with DMF,
and 17 healthy controls, for the determination of anti-Saccharomyces cerevisiae antibodies
(ASCAs), IgA and IgG. Results were categorized as following: ASCAs (units) <20 negative;
20–25 borderline positive; >25 positive. ASCAs were determined using QUANTALite ASCA
IgA/IgG ELISA (Inova Diagnostics, San Diego, CA). ELISA was performed according to the
manufacturer’s instructions, without modifications.
Statistical analysis
Patients’ characteristics were compared between psoriasis patients without DMF use, psori-
asis patients with DMF use, and healthy controls by using the one-way analysis of variance
(ANOVA), unpaired t-test and chi-square test, depending of the presence of a normal dis-
tribution. IBM SPSS 21.0 statistical software, Armonk, NY, USA was used for the statistical
analyses. In vitro data were analyzed using Graphpad Prism (version 5.1), performing paired-
t-tests.
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Results
Patients’ characteristics
There were no significant clinical differences between the groups (Table 1). Nine participants
(10%) followed a specific diet. In the psoriasis patients without DMF, one followed a sugar-free
and one a cow-milk- and wheat-free diet. In the psoriasis patients with DMF, one followed a glu-
ten-free, one a low-carbohydrate, one a both vegetarian and low-carbohydrate diet and one a
dairy-free diet. Of the healthy controls, three were vegetarian. In the electronic charts, none of
the included patients were reported to have used oral antifungal or antibiotic medication 8
weeks before the study or during the study. In the psoriasis patients without DMF, the majority
had plaques on multiple body sites (diffuse) (n = 28, 88%). Two had solely plaques on their feet,
and two solely on their head. In the psoriasis patients with DMF, plaques were located diffusely
in 26 patients (93%). One had solely psoriasis plaques on the neck and scalp, and one on the feet.
Significant reduction of S. cerevisiae abundance in psoriasis, corrected
by DMF treatment
A significant difference in S. cerevisiae abundance was demonstrated by one-way ANOVA of
the S. cerevisiae abundance between the three groups (1. psoriasis patients without DMF, 2.
Table 1. Patients’ characteristics.
Psoriasis
- DMF
Psoriasis
+ DMF
Healthy
controls
P-value1
N (patients) 30 28 32
Age (mean yrs, SD) 46.1 (13.9) 42.7 (14.1) 42.6 (14.1) P = 0.54
Gender (% female) 60.0 50.0 62.5 P = 0.52
Smoking (%) 20.0 28.6 6.3 P = 0.07
BMI (mean, SD) 27.8 (5.3) 27.2 (4.5) 25.3 (4.8) P = 0.11
Caucasian (%) 80.0 82.1 81.3 P = 0.98
Age at diagnosis
(mean yrs, SD)
30.8 (12.2) 25.4 (11.8) NA P = 0.09
Disease duration
(mean yrs, SD)
15.7 (11.6) 17.0 (11.1) NA P = 0.67
Psoriasis type n (%)
Vulgaris 25 (83.3) 25 (89.3) NA
Guttate 3 (10.0) 2 (7.1) NA
Palmoplantaris 2 (6.7) 1 (3.6) NA
Psoriasis therapy2
Immunosuppressant 2 1 NA
Local therapy 15 14 NA
UVB therapy 2 0 NA
Duration DMF (wks, mean, SD) NA 66.8 (94.0) NA
PASI3
< 10 16 (64.0) 20 (80.0) NA
>10 en 20 8 (32.0) 5 (20.0) NA
>20 1 (5.0) 0 (0) NA
DMF, dimethylfumarate; BMI, body mass index; NA, non-applicable
1 P-value calculated by one-way ANOVA for age, BMI; unpaired-t-test for age at diagnosis, disease duration; chi-square test for gender, smoking, ethnicity
2 Patient could have been on concomitant drugs
3 PASI, Psoriasis Area Severity Index for plaque type at time of sample collection (<10 mild, 10–20 moderate, >20 severe). Note that 9 of the 28 patients on
DMF are paired with the no-DMF group.
https://doi.org/10.1371/journal.pone.0176955.t001
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psoriasis patients with DMF, 3. healthy controls; p<0.001). Psoriasis patients without DMF
had a significantly lower S. cerevisiae abundance than healthy controls (mean log10 copies/g±
SD: 5.20±0.64 vs 6.25±0.63, p<0.001). Psoriasis patients using DMF had a significant higher S.
cerevisiae abundance than patients without DMF (6.04±0.72, p<0.001), reaching levels that
were similar to those of healthy controls (p = 0.233, Fig 1). Excluding the psoriasis patients
using systemic immunosuppressant’s (n = 2 without DMF, n = 1 with DMF) did not affect the
results. A subgroup analysis was performed for the patients for whom paired samples were
available, before and after DMF (n = 9). Within this group there was also a trend observed
towards an increased S. cerevisiae abundance upon DMF treatment (before DMF, 4.99±0.64;
after DMF 5.62±0.60; p = 0.086). All patients showed clinical response to DMF, and PASI
scores did not correlate to the S. cerevisiae abundance.
Fig 1. Psoriasis patients without DMF had a significantly lower faecal Saccharomyces cerevisiae
abundance than healthy controls and psoriasis patients on DMF (both p<0.001). Psoriasis patients
using DMF had similar S. cerevisiae abundance compared to healthy controls (p = 0.233). The middle line
represents the average abundance.
https://doi.org/10.1371/journal.pone.0176955.g001
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The presence of side-effects of DMF correlate with a higher S. cerevisiae
abundance
The majority (20 of 25 patients (80%), n = 3 missing) of the psoriasis patients who used DMF
reported adverse effects of DMF use. The most reported adverse effects were flushing (42.9%),
diarrhea (32.1%), abdominal pain (25.0%) and nausea (14.3%). Gastrointestinal side-effects
(abdominal pain, diarrhea and/or nausea), were reported in 17 patients on DMF, while 8
patients had no side-effects. Patients with gastrointestinal side-effects had a significant higher
S. cerevisiae abundance than patients without these side-effects (6.33±0.63 vs 5.55±0.72;
p = 0.010, Fig 2). When we included all adverse-effects, including flushing, similar results were
observed (6.26±0.63 vs 5.37±0.81; p = 0.013).
DMF directly stimulates S. cerevisiae growth in vitro
To investigate whether the increase in S. cerevisiae in faeces from patients treated with DMF was
a direct effect of DMF on the yeast itself, we treated S. cerevisiae in vitro with DMF. Results show
that DMF significantly induces S. cerevisiae growth after 24 hours in comparison to untreated
cells (p = 0.0128; Fig 3). DMF is a dimethyl ester of fumaric acid, and addition of fumaric acid
directly to S.cerevisiae also resulted in a significant increase in yeast growth (p = 0.010). Adminis-
tration of the antimycotic amphotericine-B-deoxycholate resulted, as expected, in a significant
decrease of cultured S. cerevisiae (p<0.001). In addition, to exclude the possibility that the deple-
tion of S. cerevisiae in psoriasis was due to lower faecal fumaric acid levels in these patients,
Fig 2. Psoriasis patients on DMF who had gastrointestinal side-effects had a significantly higher S.
cerevisiae abundance than psoriasis patients without the side-effects (p = 0.010).
https://doi.org/10.1371/journal.pone.0176955.g002
Depletion of S. cerevisiae in psoriasis, restored by DMF
PLOS ONE | https://doi.org/10.1371/journal.pone.0176955 May 9, 2017 6 / 11
fumaric acid measurement in faeces was performed in 16 paired psoriasis samples, without
DMF use and with DMF, and in 8 healthy controls. No significant differences in fumaric acid
levels between these groups were found (see supplementary data, in particular S2 Fig).
Anti-Saccharomyces cerevisiae antibodies (ASCAs)
The ASCA IgA level was elevated in one (3.3%) of the 30 psoriasis patients. This patient used
DMF. Two patients (6.7%) (both not on DMF) had a borderline positive ASCA IgA, compared
to one (5.9%) healthy subject (total n = 17).
The ASCA IgG level was elevated in 3 out of 30 patients (10%), of which two with and one
without DMF. One of them had also a positive IgA level. Of the healthy subjects two (11.8%)
had a positive IgG ASCA, which were different subjects than the healthy control with a positive
IgA. No correlation between a positive ASCA and faecal S. cerevisiae abundance was found.
Discussion
This study demonstrates a significant depletion of S. cerevisiae in psoriasis, which appears to
be restored in psoriasis patients on DMF. Additionally, our study confirmed that, in vitro,
DMF can directly stimulate S. cerevisiae growth.
Fig 3. DMF (1.6 mg/ml) and fumaric acid (0.46 mg/ml) significantly stimulate S. cerevisiae growth
(p = 0.01), amphotericine B-deoxycholate (amB-d) inhibits S. cerevisiaeas expected. Maximal
concentration fumaric acid used (0.46 mg/ml) was limited by the dissolvent, ethanol. Data are expressed as
mean, SD.
https://doi.org/10.1371/journal.pone.0176955.g003
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To date, information on the impact of medication on the (bacterial or fungal) microbiome
is still scarce, and this study shows we should not underestimate the consequences of medica-
tion use, whether they are beneficial or harmful to our microbiome. It is unclear whether
microbes and medication act synergistically or whether microbial changes could be a result
of the disease remission and the anti-inflammatory milieu caused by the medication. Our in
vitro data showing that DMF directly stimulates the growth of S. cerevisiae suggests that the
increased colonisation is not only the result of an anti-inflammatory environment. Recent evi-
dence shows that S. cerevisiae itself exhibits several immunomodulatory properties. The cell
wall of S. cerevisiae consists mainly of β-glucans, which has immunomodulatory effects[17],
and TNF-α reduction and IL10 stimulation by S. cerevisiae have recently been shown[5, 6].
TNF-α (pro-inflammatory) and IL10 (anti-inflammatory) are important cytokines in the path-
ogenesis of chronic inflammatory immune-mediated diseases such as psoriasis and IBD. Thus,
a higher S. cerevisiae abundance might contribute to the anti-inflammatory effect of DMF. In
addition to the immunomodulatory effects of DMF itself, a DMF-induced increase of S. cerevi-
siae might contribute to achievement (and maintenance) of stable remission in patients, pro-
viding a beneficial milieu for colonization. The finding that DMF seems to restore a (fungal)
disturbance in psoriasis, could also be extrapolated to the S. cerevisiae depletion observed in
IBD[5, 9], or potentially, MS. Psoriasis and IBD share common pathophysiological processes,
including common genetic risk factors [18, 19]. Interestingly, it was recently demonstrated
that in IBD, a risk-associated single nucleotide polymorphism (SNP) in the CARD9 gene
negatively correlates with S. cerevisiae abundance, suggesting that genetic variants affecting
immune cell function can modulate microbial abundance [5]. However, to the best of our
knowledge, the CARD9 IBD-risk allele has so far not been associated with psoriasis [19, 20].
Furthermore, while SNPs in other immunity genes may potentially contribute to an altered
microbial balance, it is important to note that such disease-associated alleles, while more prev-
alent in disease, are also present in healthy individuals, and are therefore unlikely to (solely)
explain the decreased S. cerevisiae abundance in the psoriasis cohort as compared to healthy
controls.
S. cerevisiae is one of the most abundant members of the fungal microbiota and might exert
favorable immunologic effects in immunological diseases. However, it is important to note
that from a greater perspective DMF potentially also interacts with other members of the fun-
gal and/or bacterial microbiome. Thus, while our in vitro data show a direct effect of DMF on
S. cerevisiae growth, it is also conceivable that other microbes might be able to influence S. cere-
visiae and vice versa. Therefore more research into the other members of the microbiome is
warranted.
It is of interest to note that the benefit of S. cerevisiae when used as skin-conditioning agent
has been demonstrated earlier[21]. Our study outlines the potential beneficial role of S. cerevi-
siae in skin (and gut) homeostasis. At present, S. cerevisiae is also used as dietary supplement
because of its nutrients (rich in amino acids) and functions. It is unknown whether S. cerevisiae
supplemented in food colonizes the intestine similarly as the stimulation of (probably resident)
S. cerevisiae by DMF. Some of the patients included in our study followed a particular diet
which might potentially impact the response of DMF, its side-effects and/or the S. cerevisiae
abundance, although we did not observe such trend. Interestingly, a variant of S. cerevisiae,
Saccharomyces boulardii, is already used as probiotic for diarrhea. Besides S. cerevisiae, other
members of the fungal microbiome could be of interest, and moreover, bacteria could be influ-
enced by DMF as well.
However, while the potential use of S. cerevisiae (and DMF) as probiotic is interesting, it
should, in the light of our study, be carefully implemented after further investigations into its
effect and safety[22]. Our study showed that a higher S. cerevisiae abundance might also have
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less favorable effects: the presence of gastrointestinal side-effects, such as diarrhea, nausea and
abdominal pain, which are often reported side-effects of DMF therapy, were correlated with a
significant higher S. cerevisiae abundance. Nevertheless, although in the past decades an
increasing incidence of (opportunistic) infections involving S. cerevisiae have been described
[23], S. cerevisiae, which is used in baking and brewing, is still considered to be safe and non-
pathogenic.
A strength of this patient cohort was that 93% did not use additional systemic medication,
excluding other medication bias. Future studies should include a complete paired-sample set,
and also investigate other members of the fungal microbiome in psoriasis.
In conclusion, S. cerevisiae is depleted in psoriasis patients. In in vitro and in vivo experi-
ments, DMF is able to stimulate the growth of S. cerevisiae, which might play a role in the
etiopathogenesis of psoriasis and possible also other diseases such as MS and IBD. It is also
conceivable that S. cerevisiae acts as a bystander, however not innocently, as it might be the
cause the gastrointestinal adverse-effects of DMF. Further investigations should look into the
immunologic and therapeutic functions of S. cerevisiae and the mechanistic effect of DMF
and other medications on the inhabitants of our gut. S. cerevisiae as probiotic might be a
potential candidate for novel treatments in patients with chronic inflammatory diseases such
as psoriasis.
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